ERBB2 and breast cancer: CTNeoBC (Collaborative Trials in Neoadjuvant Breast Cancer) pooled analysis showed that the frequency of pCR in patients with HR +/HER2 – tumor was the lowest, while the more aggressive subtypes, HER2 + tumors and TNBC, had increased frequencies of pCR; pCR rate of HR +/HER2 – tumor; up to 16.2% (95% CI, 6.3 – 19.3), HER2 + tumor; up to 50.3% (95% CI 45.0 – 55.5), and TNBC; up to 33.6% (95% CI, 30.9 – 36.4).